Monitor upcoming data presentations at AUA (May 15) and ISSVA (May 20) for TARA-002 in NMIBC and LMs, as positive results could drive near-term upside. Additionally, THRIVE-3 interim results in 2H 2026 represent a key catalyst for IV Choline Chloride.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $5.20entry
- T+1 · 6mo ago +1.92%α +1.15% · $5.30
- T+5 · 6mo ago −16.54%α −15.38% · $4.34
- T+20 · 5mo ago −29.81%α −29.19% · $3.65
- T+60 · 3mo ago −20.77%α −25.21% · $4.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Protara Therapeutics reported Q1 2026 net loss of $0.31 per share, beating consensus estimates of $0.37 loss, with cash of $177.4M to fund operations into 2028. Pipeline progress includes planned BLA submission for TARA-002 in lymphatic malformations in 2H 2027 and multiple data presentations in May 2026.
Key Financial Metrics
Key Facts
- Q1 2026 net loss $17.8M ($0.31/share) vs consensus $0.37 loss per share
- Cash, equivalents and marketable securities $177.4M as of March 31, 2026
- Plan to submit BLA for TARA-002 in LMs in 2H 2027
- Enrollment completion for BCG-Unresponsive cohort in ADVANCED-2 trial expected 2H 2026
- Interim results for THRIVE-3 (IV Choline Chloride) expected 2H 2026
- Research and development expenses increased to $13.6M from $9.1M in prior year period
Financial Impact
Net loss per share improved 16.2% versus consensus; cash burn rate increased with R&D expenses up 48% YoY
Risk Factors
- Clinical trial enrollment delays or negative data readouts
- Cash burn rate may require future capital raises before BLA submission
- Regulatory setbacks for TARA-002 BLA or THRIVE-3
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293938 |
Track record
13 reports on TARA
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers